News

Opinion

Editorials

Affordable cancer care needs more than price caps

Trade margin regulation must therefore be backed by closer scrutiny of manufacturers' prices and transparent reporting of sales and discounts.

Price control needs to work in concert with measures such as stronger public-health services, wider insurance coverage and more research on generics.

3 min read Oct 30, 2026 08:34 AM IST First published on: Oct 30, 2026 at 06:05 AM IST

The government’s decision to regulate trade margins on non-scheduled cancer drugs is a response to an urgent public-health concern. In recent years, new therapies have offered hope for cancer patients. At the same time, unaffordable drugs are known to be a major cause for patients delaying treatment, skipping doses or even stopping medication.…